Application of sTREM2-NCL-AKT / eNOS axis in ovarian cancer vascular permeability and malignant ascites formation
By targeting the sTREM2 axis and developing substances that block sTREM2, the treatment challenge of malignant ascites in ovarian cancer has been solved, achieving a significant reduction in ascites volume and tumor burden, and providing a safe and precise treatment strategy.
CN121337992APending Publication Date: 2026-01-16THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV
1 Cites 0 Cited by
Patent Information
- Application Number
- CN202511330232.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-17
- Publication Date
- 2026-01-16
AI Technical Summary
Technical Problem
Current treatments for malignant ascites in ovarian cancer fail to address the underlying pathophysiological mechanisms and often carry risks of infection and metabolic disorders, limiting the availability of targeted therapies.
Method used
By targeting the sTREM2 axis, substances that block sTREM2, such as small interfering RNA and scFv antibodies, can be developed to inhibit the expression or activity of sTREM2 or its related proteins, thereby reducing the formation of malignant ascites in ovarian cancer.
Benefits of technology
It significantly reduces ascites volume in ovarian cancer, lowers tumor burden, reduces vascular leakage, provides prognostic biomarkers and potential therapeutic targets, avoids the systemic effects of VEGF inhibitors, and is both safe and precise.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention belongs to the technical field of cancer treatment, and discloses an application of an sTREM2-NCL-AKT / eNOS axis in the vascular permeability of ovarian cancer and the formation of malignant ascites. The invention proves that the level of the sTREM2 is increased in ascites of an ovarian cancer patient, discloses the effect of the sTREM2 in promoting vascular permeability and driving ascites formation, and puts forward that the sTREM2 has double values of a prognosis biomarker and a potential treatment target. The discovery lays a foundation for developing accurate treatment for ovarian cancer and malignant ascites. In mechanism, the sTREM2 activates an AKT / eNOS signal channel through interaction with a cell surface nucleolin (NCL) protein, so that the integrity of an endothelial barrier is damaged. Targeting or blocking sTREM2 effectively mitigates vascular leakage and ascites production. According to the discovery, the sTREM2 is determined as a core driving factor of ascites pathogenesis, and the potential of the sTREM2 as an ovarian cancer treatment target is highlighted.
Need to check novelty before this filing date? Find Prior Art